NVAX
NVAX clinical trials: NOVAVAX INC
Every trial on ClinicalTrials.gov where NOVAVAX INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 53
- Trials linked
- 47
- As lead sponsor
- 6
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NVAX on the catalyst calendar · NVAX registry changes
- Primary completion Oct 9, 2026ActualPhase 4NCT07086222Efficacy and Safety of NVX-CoV2705Novavax · COVID-19TerminatedNVAXLeadSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 24, 2025ActualPhase 3NCT06291857A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2024ActualPhase 4NCT06633835Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United StatesNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2024ActualPhase 2/Phase 3NCT05468736Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 17, 2022ActualPhase 3NCT05463068Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2024ActualPhase 3NCT06409663A Strain Change Study for SARS-CoV-2 rS VaccinesNovavax · Severe Acute Respiratory Syndrome Coronavirus 2 InfectionCompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2024ActualPhase 3NCT05973006Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 11, 2023ActualPhase 3NCT05875701Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 29, 2022ActualPhase 3NCT04583995A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United KingdomNovavax · SARS-CoV-2 InfectionCompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2018ActualPhase 3NCT02624947A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal ImmunizationNovavax · Respiratory Syncytial Virus InfectionsCompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2021ActualPhase 1/Phase 2NCT04961541Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination VaccineNovavax · SARS-CoV InfectionCompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 4, 2025ActualPhase 2/Phase 3NCT06485752Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza VaccineNovavax · COVID-19WithdrawnNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 16, 2025Sponsor estimatePhase 2/Phase 3NCT06482359Lot Consistency Study of COVID-19 and Influenza Combination VaccineNovavax · COVID-19WithdrawnNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2024ActualPhase 2/Phase 3NCT05925127Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS VaccinesNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 25, 2023ActualPhase 2NCT05519839A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination VaccineNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2023ActualPhase 2/Phase 3NCT05975060A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated...Novavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 17, 2022ActualPhase 3NCT05372588Phase 3 Boosting Study for the SARS-CoV-2 rS Variant VaccinesNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 10, 2023ActualPhase 3NCT04611802A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in...Novavax · SARS-CoV InfectionCompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2020ActualPhase 3NCT04120194Phase 3 Pivotal Trial of NanoFlu™ in Older AdultsNovavax · Influenza, HumanCompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2022ActualPhase 1/Phase 2NCT04368988Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M AdjuvantNovavax · COVID-19CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 23, 2022ActualPhase 2NCT05112848A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)Novavax · SARS-CoV-2 InfectionCompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 14, 2018ActualPhase 1/Phase 2NCT03293498Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)Novavax · InfluenzaCompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2019ActualPhase 2NCT03658629Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older AdultsNovavax · Influenza, HumanTerminatedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 3NCT02608502A Study to Evaluate the Efficacy of an RSV F Vaccine in Older AdultsNovavax · Respiratory Syncytial Virus (RSV)CompletedNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2022Sponsor estimatePhase 1/Phase 2NCT05029856Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in AdultsNovavax · Covid19WithdrawnNVAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 28 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner